Evidence memo / Skin & pigmentation

Glutathione

Also: GSH · IV glutathione · gluta drip · reduced glutathione · L-glutathione

The body's main endogenous antioxidant, sold by drip clinics as an intravenous skin-lightening and wellness treatment for which no published clinical trial establishes efficacy and at least one national regulator has issued a public safety advisory.

Claim-specific / contestedSafety/regulatory watchSafety / regulatory watch

The verdict

Our read at a glance.

Whether infusing a tripeptide the body already makes produces skin lightening, detoxification, or general wellness benefits that justify intravenous administration.

The signal
Glutathione is a tripeptide of glutamate, cysteine and glycine, and its role in cellular antioxidant defence is not in question. The skin-lightening use is a different claim: reviews of the evidence describe it as substantially unproven, and the safety literature states there are no published clinical trials evaluating injectable glutathione for skin lightening, nor published guidance on dose or duration for that use.
The unknown
Whether infused glutathione meaningfully raises intracellular glutathione where it would need to act, what dose or duration would be required for any cosmetic effect, and whether any effect persists. Oral bioavailability is a separate and long-standing question that the skin-lightening literature does not resolve.
Our read
A real molecule with a real biological role, sold for a use that has essentially no trial evidence behind it and a documented mechanism for harm that comes mostly from the needle and the setting rather than the molecule. Being endogenous is not the same as being safe to infuse at high dose in a salon.

The mechanism

How it works.

Safety & regulatory boundary

The consequential part.

The Philippine FDA, the regulator most engaged with this practice, has approved injectable glutathione only as an adjunct in cisplatin chemotherapy and issued a public advisory against its use for skin lightening, citing possible hepatic, renal and neurological toxicity, Stevens-Johnson syndrome, and transmission of infectious agents when infusions are given in non-sterile settings by non-medical practitioners. That is a Philippine action, not a US FDA one. A published case describes systemic inflammatory response syndrome after a high-dose intravenous glutathione-containing infusion. Compounded drip formulations frequently pair it with high-dose vitamin C, which carries its own renal considerations.

What's next

What we're watching.

Any registered controlled trial of injectable glutathione for a cosmetic endpoint, pharmacokinetic work showing what infusion does to tissue glutathione, and further regulator action in other markets.

Context

Why this is discussed.

Glutathione genuinely is central to antioxidant defence, which makes the pitch sound mechanistically obvious, and drip clinics have turned it into a routine cosmetic service in many countries.

The evidence base

5 cited references.

Regulatory & labels1

FDA Advisory No. 2019-182: Unsafe use of glutathione as a skin lightening agent

Food and Drug Administration, Republic of the Philippines · 2019

Indexed literature (PubMed)4

Intravenous glutathione for skin lightening: Inadequate safety data

Davids LM, van Wyk J, Khumalo NP, Jablonski NG (S Afr Med J) · 2016

Glutathione as a skin whitening agent: Facts, myths, evidence and controversies

Sonthalia S, Daulatabad D, Sarkar R (Indian J Dermatol Venereol Leprol) · 2016

Glutathione for skin lightening: a regnant myth or evidence-based verity?

Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D (Dermatol Pract Concept) · 2018

Keep reading

Related published memos.